MASH Program
Metabolic dysfunction-associated steatohepatitis (MASH) / Inflammatory Diseases
PreclinicalActive (in collaboration)
Key Facts
Indication
Metabolic dysfunction-associated steatohepatitis (MASH) / Inflammatory Diseases
Phase
Preclinical
Status
Active (in collaboration)
Company
About Sprint Bioscience
Sprint Bioscience is a preclinical-stage biotech company leveraging fragment-based drug discovery to develop novel oncology therapeutics. Its capital-efficient business model centers on advancing programs to a preclinical proof-of-concept before out-licensing them to larger pharma partners, as demonstrated by a major deal with Gilead Sciences. The company is expanding its pipeline into metabolic/inflammatory diseases through collaborations, aiming to address high-need areas with significant commercial potential.
View full company profile